Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2248-2253

  Ji, Na Young ^a,b   Kim, Young Ho ^c   Jang, Ye Jin ^a   Kang, Yun Hee ^a   Lee, Chung Il ^a   Kim, Jae Wha ^a   Yeom, Young Il ^a   Chun, Ho Kyung ^c   Choi, Yoon Ho ^c   Kim, Joo Heon ^d   Kim, Jong Wan ^e   Lee, Hee Gu ^a   Song, Eun Young ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Eulji University School of Medicine   (South Korea)

^e Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; MEMBRANE PROTEIN; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

ACCURACY; AGED; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; ADULT; BLOOD; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; PROTEOGLYCANS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77957045820     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01665.x     Document Type: Article

References (22)

1. Ahlquist DA, Wieand HS, Moertel CG. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993, 269:1262-7.
2. Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol 2002, 13:51-6.
3. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005, 142:81-5.
4. Roessler M, Rollinger W, Palme S. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 2005, 11:6550-7.
5. Melle C, Ernst G, Schimmel B. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005, 129:66-73.
6. Habermann JK, Roblick UJ, Luke BT. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131:1020-9. quiz 284
7. Kim HJ, Yu MH, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008, 41:685-92.
8. Greene FL. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol 2003, 21:23-9.
9. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr 2007, 96:338-41.
10. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 2007, 96:487-91.
11. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007, 96:644-7.
12. Sarrazin S, Adam E, Lyon M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006, 1765:25-37.
13. Lassalle P, Molet S, Janin A. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996, 271:20458-64.
14. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 2002, 63:159-71.
15. Scherpereel A, Gentina T, Grigoriu B. Overexpression of endocan induces tumor formation. Cancer Res 2003, 63:6084-9.
16. Rennel E, Mellberg S, Dimberg A. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007, 313:1285-94.
17. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009, 54:389-94.
18. Maurage CA, Adam E, Mineo JF. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 2009, 68:633-41.
19. Grigoriu BD, Depontieu F, Scherpereel A. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006, 12:4575-82.
20. Zuo L, Zhang SM, Hu RL. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 2008, 14:4562-8.
21. Bechard D, Scherpereel A, Hammad H. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001, 167:3099-106.
22. Bechard D, Meignin V, Scherpereel A. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000, 37:417-25.